Thrivent Financial for Lutherans Has $720,000 Stake in Waters Corporation $WAT

Thrivent Financial for Lutherans cut its stake in Waters Corporation (NYSE:WAT) by 99.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,402 shares of the medical instruments supplier’s stock after selling 274,649 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Waters were worth $720,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of WAT. Deroy & Devereaux Private Investment Counsel Inc. increased its position in Waters by 41.9% in the third quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 13,802 shares of the medical instruments supplier’s stock worth $4,138,000 after buying an additional 4,077 shares during the last quarter. Envestnet Asset Management Inc. grew its stake in shares of Waters by 5.0% during the 2nd quarter. Envestnet Asset Management Inc. now owns 126,070 shares of the medical instruments supplier’s stock worth $44,004,000 after acquiring an additional 5,980 shares during the period. Figure 8 Investment Strategies LLC increased its holdings in Waters by 46.4% in the 3rd quarter. Figure 8 Investment Strategies LLC now owns 7,793 shares of the medical instruments supplier’s stock worth $2,336,000 after acquiring an additional 2,471 shares during the last quarter. Union Bancaire Privee UBP SA purchased a new stake in Waters in the 3rd quarter worth about $1,624,000. Finally, Quilter Plc lifted its holdings in Waters by 8.1% during the third quarter. Quilter Plc now owns 43,320 shares of the medical instruments supplier’s stock valued at $12,988,000 after purchasing an additional 3,229 shares during the last quarter. Institutional investors own 94.01% of the company’s stock.

Waters Stock Up 1.3%

WAT opened at $323.91 on Tuesday. Waters Corporation has a one year low of $275.05 and a one year high of $414.15. The company has a fifty day moving average price of $379.34 and a 200-day moving average price of $348.42. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.41 and a quick ratio of 1.01. The firm has a market capitalization of $19.29 billion, a P/E ratio of 30.07, a price-to-earnings-growth ratio of 2.23 and a beta of 1.18.

Waters (NYSE:WAT) last issued its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $4.53 EPS for the quarter, topping analysts’ consensus estimates of $4.50 by $0.03. The firm had revenue of $932.36 million for the quarter, compared to analyst estimates of $928.17 million. Waters had a net margin of 20.30% and a return on equity of 34.79%. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $4.10 EPS. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. Equities research analysts expect that Waters Corporation will post 12.86 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on WAT. Morgan Stanley started coverage on shares of Waters in a research report on Monday, December 1st. They issued an “equal weight” rating and a $423.00 price target on the stock. HSBC started coverage on shares of Waters in a research note on Tuesday, January 27th. They issued a “buy” rating and a $460.00 price objective for the company. Wolfe Research upgraded Waters from a “peer perform” rating to an “outperform” rating and set a $480.00 target price on the stock in a research report on Wednesday, December 10th. UBS Group cut their price target on Waters from $395.00 to $370.00 and set a “neutral” rating for the company in a report on Tuesday, February 10th. Finally, Citigroup began coverage on Waters in a research report on Tuesday, February 10th. They issued a “buy” rating and a $425.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $397.68.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.